Recent advances in postoperative pulmonary rehabilitation of patients with non‑small cell lung cancer (Review)

Abstract

Non-small cell lung cancer (NSCLC) accounts for ~85% of lung cancer cases and has high morbidity and mortality rates. Over the past decade, treatment strategies for NSCLC have progressed rapidly, particularly with the increasing use of screening programs, leading to improvements in the initial diagnosis and treatment of early-stage and preinvasive tumors. Surgical intervention remains the primary treatment for early-stage NSCLC. Thoracoscopic lobectomy has become the main treatment for early-stage NSCLC, as it results in less postoperative bleeding and pain and fewer complications. However, the complication rate for thoracoscopic lobectomy due to sputum retention and weakened respiratory muscle strength remains as high as 19-59%. Treating NSCLC remains challenging in terms of postoperative pulmonary rehabilitation. In the present review, recent advances in postoperative pulmonary rehabilitation for patients with NSCLC were presented in order to assist researchers in developing improved treatments to enhance postoperative pulmonary rehabilitation for such patients. Contents 1. Introduction 2. NSCLC stages and status of lung cancer surgery 3. Postoperative pulmonary rehabilitation for patients with NSCLC 4. Current pulmonary rehabilitation for patients with NSCLC 5. Limitations of postoperative pulmonary rehabilitation 6. Conclusions and perspectives

Effect of lung rehabilitation training combined with nutritional intervention on patients after thoracoscopic resection of lung cancer

“…Respiratory muscle strength training, especially strength training for the inspiratory muscles, has been indicated to significantly enhance exercise capacity, improve respiratory function and reduce dyspnea (23). A study by Su et al (24) also highlighted the crucial role of pulmonary rehabilitation in diverse clinical scenarios. This comprehensive approach has been shown to effectively decrease the occurrence of pulmonary complications, enhance lung function and ultimately enhance the overall quality of life.…”

The METTL3/miR-196a Axis Predicts Poor Prognosis in Non-small Cell Lung Cancer

“…Lung cancer is one of the most common malignancies, resulting in approximately 1.6 million deaths every year. Non-small cell lung cancer (NSCLC) is the major subtype of lung cancer (approximately 85% of lung cancer cases), including lung squamous cell carcinoma and lung adenocarcinoma, which is the leading cause of cancer death worldwide [1]. Lung cancer is a primary cancer type with high morbidity and mortality in China [2].…”

The DC–T cell axis is an effective target for the treatment of non‐small cell lung cancer

“…From a histopathological perspective, lung cancer has two major classifications: small and non‐small cell lung cancers (SCLC and NSCLC, respectively). The latter accounts for around 85% of all lung cancer cases, with a 5‐year overall survival (OS) rate of about 15% 6–8 . Thus, it is of particular importance to identify more critical factors influencing the treatment efficacy of NSCLC.…”

“…The latter accounts for around 85% of all lung cancer cases, with a 5-year overall survival (OS) rate of about 15%. [6][7][8] Thus, it is of particular importance to identify more critical factors influencing the treatment efficacy of NSCLC.…”